Two Sides of the Same Coin: EGFR Exon 19 Deletions and Insertions in Lung Cancer

Yale University School of Medicine, New Haven, CT, USA.
Clinical Cancer Research (Impact Factor: 8.19). 02/2012; 18(6):1490-2. DOI: 10.1158/1078-0432.CCR-11-3282
Source: PubMed

ABSTRACT Most lung adenocarcinoma-associated EGF receptor (EGFR) mutations confer sensitivity to specific EGFR tyrosine kinase inhibitors. The finding that exon 19 insertion mutations are also sensitive to this class of drugs suggests that testing for these mutations should be done and that these patients will benefit from treatment with tyrosine kinase inhibitors.

  • Source
    Clinical and Translational Oncology 05/2012; 14(5):321-2. DOI:10.1007/s12094-012-0802-6 · 2.08 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Over the past three decades, mortality from lung cancer has sharply and continuously increased in China, ascending to the first cause of death among all types of cancer. The ability to identify the actual sequence of gene mutations may help doctors determine which mutations lead to precancerous lesions and which produce invasive carcinomas, especially using next-generation sequencing (NGS) technology. In this study, we analyzed the latest lung cancer data in the COSMIC database, in order to find genomic "hotspots" that are frequently mutated in human lung cancer genomes. The results revealed that the most frequently mutated lung cancer genes are EGFR, KRAS and TP53. In recent years, EGFR and KRAS lung cancer test kits have been utilized for detecting lung cancer patients, but they presented many disadvantages, as they proved to be of low sensitivity, labor-intensive and time-consuming. In this study, we constructed a more complete catalogue of lung cancer mutation events including 145 mutated genes. With the genes of this list it may be feasible to develop a NGS kit for lung cancer mutation detection.
    Genetics and Molecular Biology 09/2013; 36(3):455-464. DOI:10.1590/S1415-47572013000300022 · 0.88 Impact Factor


Available from